Ironwood Pharmaceuticals (IRWD) Revenue (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Revenue data on file, last reported at $106.5 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 158.87% year-over-year to $106.5 million; the trailing twelve-month figure through Mar 2026 stood at $361.5 million (up 13.8% YoY), and the FY2025 full-year result was $296.2 million, down 15.72% from the prior year.
• Revenue advanced to $106.5 million in Q1 2026, from $47.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $122.1 million in Q3 2025 to a low of $41.1 million in Q1 2025.
• A 5-year average of $94.6 million and a median of $97.5 million in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue tumbled 47.31% in 2025 and jumped 158.87% in 2026, its largest moves.
• Tracing IRWD's Revenue over 5 years: stood at $107.2 million in 2022, then grew by 9.66% to $117.6 million in 2023, then retreated by 22.98% to $90.5 million in 2024, then plunged by 47.31% to $47.7 million in 2025, then surged by 123.24% to $106.5 million in 2026.
• Business Quant data shows IRWD's Revenue at $106.5 million in Q1 2026, $47.7 million in Q4 2025, and $122.1 million in Q3 2025.